Patents by Inventor Daniel Lawton
Daniel Lawton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11925717Abstract: A photosensitizer formulation can be disposed on or in a mesh; net; netting; screen; curtain of strands, fibers, or monofilaments; substrate, personal protective gear, mask, or any other suitable object. The photosensitizer formulation, when in contact with molecular oxygen and activated by light or ultrasound, produces microbicidal singlet oxygen. A variety of different arrangements and applications are described. For example, an air flow device may also be included to generate a flow of air through or over the photosensitizer formulation. A fluorescent formulation may be included to monitor photobleaching. The photosensitizer formulation may be disposed in a concentration gradient to generate antigenic particles by damaging or destroying microbes.Type: GrantFiled: October 3, 2022Date of Patent: March 12, 2024Assignee: Singletto Inc.Inventors: James Chongchu Chen, Celesta Jane Bjornson, John David Bjornson, LuAnn Lawton Chen, Stephanie Marie Chong-Ming Chen, Daniel Duong Hoang, Kathleen Clare Lendvay, Paul Deven Rolley
-
Publication number: 20240059649Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: October 17, 2023Publication date: February 22, 2024Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20210395194Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: March 29, 2021Publication date: December 23, 2021Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10961187Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: June 17, 2019Date of Patent: March 30, 2021Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20190315683Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: June 17, 2019Publication date: October 17, 2019Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10358414Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers? disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: April 7, 2017Date of Patent: July 23, 2019Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10112897Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: March 15, 2017Date of Patent: October 30, 2018Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton
-
Publication number: 20170210716Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers? disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: April 7, 2017Publication date: July 27, 2017Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20170183303Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: March 15, 2017Publication date: June 29, 2017Applicant: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton
-
Patent number: 9630937Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: November 7, 2014Date of Patent: April 25, 2017Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Publication number: 20160287563Abstract: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.Type: ApplicationFiled: June 6, 2016Publication date: October 6, 2016Applicant: Promentis Pharmaceuticals, Inc.Inventors: Daniel Lawton, Michael Neary, James A. Nieman
-
Patent number: 9457014Abstract: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.Type: GrantFiled: July 30, 2012Date of Patent: October 4, 2016Assignee: Promentis Pharmaceuticals, Inc.Inventors: Daniel Lawton, Michael Neary, James A. Nieman
-
Publication number: 20160081987Abstract: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.Type: ApplicationFiled: July 30, 2012Publication date: March 24, 2016Applicant: PROMENTIS PHARMACEUTICALS, INC.Inventors: Daniel Lawton, Michael Neary, James A. Nieman
-
Publication number: 20150133544Abstract: A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton
-
Publication number: 20150133470Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 9012674Abstract: A novel substituted N-acetyl-L-cysteine (NAC) derivative and methods of using this compound for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: November 7, 2014Date of Patent: April 21, 2015Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton
-
Publication number: 20070185775Abstract: A transaction system and method is provided for enabling potential buyers to purchase goods through reverse on-line auction process. The transaction system is configured to automatically receive periodic uploads of information regarding goods for sale by suppliers and to store this information in a database. A potential buyer can login to the transaction system and submit searches for goods based on a variety of parameters which may include condition, warranty, and revision. The potential buyer also submits an offer price for each requested item. The transaction system queries the database to determine if the requested goods are available. The transaction system selects the vendor so as to maximize the sales margin and then determines whether the buyer's offer can be accepted based on predetermined margin requirements. If the buyer's offer can be accepted, the system generates an acceptance to the offer from the buyer and generates a purchase order to the selected supplier.Type: ApplicationFiled: February 7, 2006Publication date: August 9, 2007Inventor: Daniel Lawton